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1052-188 Safety and Efficacy of Siroiimus-Eiuting Stent (cypher) 
in Acute Myocardiai infarction: A substudy of the 
Rapamycin-Eiuting Stent Evaluation at Rotterdam 
Cardiology Hospital (RESEARCH) Study 
Chi Hanq Lea Pedro A. Lemos, Ron T. van Domburg, George Sianos, Pieter C. Smits, 
Willem J. van der Giessen, Pim de Feyter, Patrick W. Serruys, Thoraxcenter, Erasmus 
Medical Center Rotterdam, Rotterdam, The Netherlands 
Background: Cypher stent reduces restenosis in stable pts with simple lesions. Our aim 
is to assess the safety and efficacy of cypher stent in AMI pts. 
Methods: AMI pts admitted for PCI during the 6 mths period (16th Apr.15th Ott 0.2) were 
screened for eligibility for cypher stent. AMI pts who underwent PCI during the prior 6 
mths (16th Ott Ol-15th Apr 02) were recruited as historic control. 
Results: Up to 27th Aug 02. totally 92 AMI pts (presented wfthin 6 hrs) were screened 
and 66 (72%) were recruited (cypher gp). These 66 accounted for 17% of the 384 pts 
who were recruited in the RESEARCH study during the same period. Reasons for exclu- 
sion were stent diameter unavailable (n=17), length unavailable (n=l) or physician pref- 
erence (n=8). Among pts (70% male) in the cypher gp, the average age was 66+/-i 4 yrs. 
Risk factors were smoking (24%). DM (7.6%). HT (52%) hypercholesterolemia (52%) 
and adverse family history (33%). Peak CK was 3367+/-2239 IUIL. Anterior MI 
accounted for 50% of infarction. Average 1.5 stents (i-5) were implanted per pt. Majority 
(80%) received 3-mm diameter stent. Post-procedural diameter stenosis by QCA 
changed from 80+/-20 to 11 +I-5%. The procedural success rate was 92% with 8% failed 
to achieve TIMI 3 flow. Average follow-up period was 2.2 mths (2.0-4.5). There was no 
stent thrombosis. The cypher gp showed a positive trend towards reduction in repeat 
revascularization rate (figure). 
Conclusion: Cypher stent is safe and effective in reducing the repeat revascularization 
rate in pts presented with AMI. 
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1053-l 73 A Randomized Double Blind Placebo Controlled 
Multicenter Pilot Study of the Safety and Feasibility of 
AQVVEGFIZ1.10 via an intramyocardiai injection 
Catheter in Patients With Advanced Coronary Artery 
Disease 
Shmuel Fuchs, Nabil Dib, Barry Cohen, Petros G. Okubagzi, Edward B. Diethrich, Ann 
Campbell, Jennifer Macko, Henrik Rasmussen, Stephen E. Epstein, Cardiovascular 
Research Institute, Washington Hospital Center, Washington, DC, Arizona Heart 
Institute, Phoenix, AZ 
Background: This phase 1. randomized, double blind, placebo controlled pilot study 
evaluated, for the first time, the safety and feasibility of percutaneous catheter-based 
delivery of an adenovector.AdovVEGF121 .lO(AdVEGF), a replication-deficient adenovi- 
rus carrying the transgene encoding for VEGF121, was administered to patients with 
severly symptomatic coronary artery disease (CCS angina class III or IV) not amenable 
to conventional revascularization procedures. 
Methods: Ten patients were randomized (2:l) to receive AdVEGF (4X10’“pu) or diluent 
(placebo), as fifteen 1OOpL endomyocardial fnjections, distributed evenly across the left 
ventricle using a non-flouroscopic, 3-dimensional mapping injection catheter system. 
Results: Treatment was successfully administered in all cases. Median time of total 
catheterization procedure and from first to last injection was 2.5 hrs (range: 1.4 _ 3.2 hrs) 
and 34 mins (range: 12 - 73 mins) respectively. One case of moderate vomiting and two 
cases of mildly elevated CPK (one AdVEGF and one placebo patient) were considered 
related to procedure. AdVEGF was well tolerated and only one treatment-related event, 
transient periprocedural fever, was observed. All adenoviral cultures (urine and throat 
swab) were negative, and no significant changes in plasma VEGF levels were noted. At 
up to 12 months follow-up, no cancers, proliferative retinal changes, or significant abnor- 
malities in hepatic, renal or hematological indices were observed. At week 12, change 
from baseline in time to an additional lmm ST depression on exercise ECG for AdVEGF 
group trended towards improvement, while the placebo group deteriorated slightly. 
Conclusions: Catheter-basedendomyocardial injection of AdVEGF is practical, feasible 
and safe, and is associated with no systemic viral distribution. A randomized, phase II 
‘proof-of-concept, study is warranted. 
1053-l 74 Effective Stent-Based Delivery of Tissue inhibitor of 
Metaiioproteinase 3 to Porcine Coronary Arteries Using 
a Novel Biosynthetic Stent Coating 
Thomas W. Johnson, Yin Xiong Wu, Christian Herdeg. Andreas Baumbach, Andrew C. 
Newby, Karl R. Karsch, Martin Oberhoff, Bristol Heart Institute, Bristol, United Kingdom, 
University of Tubingen. Tubingen, Germany 
Background: In-stent restenosis continues to pose a problem for the longterm success 
rate of percutaneous coronary intervention. We aimed to develop a suitable vehicle for 
the local delivery of a therapeutic adenovirus to coronary arteries, resulting in over- 
expression of Tissue Inhibitor of Metalloproteinase 3 (TIMPS). TIMP3 is known to induce 
apoptosis of vascular smooth muscle cells, thus reducing nsointima formation. 
Method: We used a Matrix HI phosphorylocholine coated (PC) stent (Biocompatibles. 
Farnham, U.K.), with enhanced cationic charge to increase viral transduction efficiency to 
porcine coronaries. 
Preliminary studies to evaluate the coating & optimal viral dosing were performed with 
uncoated and PC-stainless steel coupons. Subsequently, stents pretreated with ~Galac- 
tosidase adenovirus, were implanted, invitro, in porcine coronary arteries 8 flushed with 
1 of 5 solutions - no flush, 0.9% saline, contrast media, blood, or culture medrum (n=5 for 
each group). The stented arteries were cultured for 48hours. fixed & stained with X-Gal 
to confirm viral transduction. Transduction was quantified ‘en-face’ using Image Pro. 
lnvivo transduction was first assessed with p-Gal PC-stents in porcine coronaries & fol- 
lowing this, TIMP3 stents were implanted for up to 7 days. Harvested tissues were analy- 
serf for presence of virus & gene product using PCR & immune-histochemical methods. 
Results: PC-stalnless steel coupons showed superior p-Gal transduction rates com- 
pared to uncoated coupons. Invitro transduction rates were; No Flush 6.9+/-3.7%. 0.9% 
Saline 6.6+/-3.6, Culture Medium 7.2+/-2.5%, Contrast Medium 7.4+/-l .9%. & Blood 
16.2+/-9.3%. Invivo, we demonstrated localized transduction of p-Gal, & more impor- 
tantly, TIMP3 without systemic distribution of the virus, up to 7 days after implantation. 
Conclusion: Our results demonstrate effective, in-vitro & in-viva, transduction of aden- 
ovirus from a stent using a novel biosynthetic coating, already licensed in humans, Addi- 
tionally, we demonstrated effective & localised production of TIMP3 in stented 
coronaries. The combination of TIMP3 & a PC stem is a potentially attractive candfdate 
for the prevention of in-stent restenosis. 
1053-I 76 Endovascuiar Cryotherapy increases Luminal Area in 
the Focally Atherosclerotic Hyperchoiesteroiemic 
Rabbit 
Christopher J. Davis Joshua J. Fischer, John M. Sanders, Daniel K. Bennett. Mike Urick. 
Patrick Chauvet. Ian J. Sarembock. University of Virginia Health System, Charlottesville, 
VA, CryoCath Technologies, Montreal, PQ, Canada 
Background: There is recent interest in the use of cryotherapy to treat atherosclerotic 
lesions. The objective of this study was to characterize the effects of endovascular cryo- 
therapy on vessel wall components in the hypercholesterolemic, focally atherosclerotic 
rabbit. 
Methods: Bilateral focal femoral atherosclerosis was induced by air desiccation in twenty 
New Zealand White rabbits. Animals were then placed on a 0.5% cholesterol diet for 28 
days. Utilizing a cryo-balloon system, vessels underwent a sham procedure (n=lO) or 
cryotherapy at 4 temperatures: -2O”C(n= 4) -1O”C(n=8), O”C(n=8). and +lO’C(n=lO). 
Animals were placed on a chow diet for 28 days post cryotherapy at which time animals 
were euthanized and arteries harvested for analysis. 
Results: Vessels treated at +lO”C had significantly larger external elastic lamina (EEL) 
and luminal area (2.13+0.12 mm2 vs. 1.2320.16 mm2, p=.OOO4; 0.85*0.10 mm2 vs. 
0.51+0.12 mm2, p=.O4) together with a higher macrophage content and lower total vessel 
collagen content compared with sham controls (50.4A4.9 % vs. 26.75r6.9 %, p=.Ol; 
52.323.3 % vs. 64.Oi3.2 %). Vessels in the other groups were not different from sham 
controls although a trend for larger EEL area (1.7&0.25 vs. 1.23t0.16 mm*, p=.O7) and 
a trend for increased neointimal/medial collagen content (44.7*6.8% vs. 32.6*4.9%, p= 
.I5 ) were seen at -10°C. The cross sectional area of narrowing by plaque (CSAN-P) 
and smooth muscle cell content were similar among groups. 
Conclusions: Endovascular cryotherapy at +lO”C significantly increases luminal and 
EEL area of focally atherosclerotic arteries without a change in CSAN-P, consistent with 
a positive remodeling effect. Furthermore, there were more macrophages and less col- 
lagen deposition in these vessels. which may have facilitated positive remodeling. A 
trend for increased EEL area was also seen at -10°C as well as increased collagen con- 
tent in the neointima and media, which may enhance plaque stability Further studies of 
this novel technique utilizing various treatment temperatures and regimens are currently 
in progress. 
